Instruct: Identify the main and secondary category of Arxiv papers based on the titles and abstracts
Query: Bayesian dose-regimen assessment in early phase oncology incorporating
  pharmacokinetics and pharmacodynamics   Phase I dose-finding trials in oncology seek to find the maximum tolerated
dose (MTD) of a drug under a specific schedule. Evaluating drug-schedules aims
at improving treatment safety while maintaining efficacy. However, while we can
reasonably assume that toxicity increases with the dose for cytotoxic drugs,
the relationship between toxicity and multiple schedules remains elusive. We
proposed a Bayesian dose-regimen assessment method (DRtox) using
pharmacokinetics/pharmacodynamics (PK/PD) information to estimate the maximum
tolerated dose-regimen (MTD-regimen), at the end of the dose-escalation stage
of a trial to be recommended for the next phase. We modeled the binary toxicity
via a PD endpoint and estimated the dose-regimen toxicity relationship through
the integration of a dose-regimen PD model and a PD toxicity model. For the
dose-regimen PD model, we considered nonlinear mixed-effects models, and for
the PD toxicity model, we proposed the following two Bayesian approaches: a
logistic model and a hierarchical model. We evaluated the operating
characteristics of the DRtox through simulation studies under various
scenarios. The results showed that our method outperforms traditional
model-based designs demonstrating a higher percentage of correctly selecting
the MTD-regimen. Moreover, the inclusion of PK/PD information in the DRtox
helped provide more precise estimates for the entire dose-regimen toxicity
curve; therefore the DRtox may recommend alternative untested regimens for
expansion cohorts. The DRtox should be applied at the end of the
dose-escalation stage of an ongoing trial for patients with relapsed or
refractory acute myeloid leukemia (NCT03594955) once all toxicity and PK/PD
data are collected.

33
The categories of this paper are: plasm-ph
17
The categories of this paper are: q-fin
19
The categories of this paper are: eess
18
The categories of this paper are: econ
7
The categories of this paper are: hep-th
8
The categories of this paper are: hep-ex
27
The categories of this paper are: comp-gas
37
The categories of this paper are: supr-con
21
The categories of this paper are: adap-org
12
The categories of this paper are: nucl-th
36
The categories of this paper are: cmp-lg
3
The categories of this paper are: physics
11
The categories of this paper are: hep-lat
5
The categories of this paper are: gr-qc
23
The categories of this paper are: solv-int
34
The categories of this paper are: chem-ph